Sebastian Gensior

1. Introduction: The Gospel of the Target In the parlance of modern pharmaceuticals, few words carry the theological weight of "target." Scientists chant it, investors demand it, and regulators inquire after it with the reverence of high priests examining relics. If one believes the marketing, every drug these

I. Introduction: The Double-Edged Scalpel of AI in Drug Discovery The relentless pursuit of new medicines remains a cornerstone of human health, yet it is a quest characterized by exorbitant costs, protracted timelines, and a notoriously high failure rate.The traditional drug development pipeline, from initial discovery to market

The Return of the “Magic Bullet” In 1908, the German scientist Paul Ehrlich coined the term “Zauberkugel” – magic bullet – envisioning a drug that could target disease with pinpoint accuracy while sparing healthy tissue. Over a century later, antibody–drug conjugates (ADCs) aim to fulfill that vision. An ADC couples a

The Next Big Patent Cliff Looms Pharmaceutical investors are once again bracing for what industry insiders ominously dub a “patent cliff.” In 2027-2028 alone, drugs accounting for roughly $180 billion in annual sales – nearly 12% of the global pharma market – will lose patent protection. This wave includes some of

The first half of 2025 saw an unprecedented surge in royalty-based financings and structured revenue deals across the biopharmaceutical sector. Faced with a bleak equity market and tightening credit, drug developers from Boston to Basel turned to royalty monetization as a lifeline. In the span of January to June

Trials, Errors, and Timely Trades In the rarefied world of biotech, miracles in the lab often meet murkier practices in the market. Consider a small Massachusetts biotech last year: as it anxiously awaited a pivotal clinical trial readout, a curious flurry of phone calls and stock sales began emanating from

A Corporate Pastoral in Four Acts By one who has seen the lanyards and despaired. DRAMATIS PERSONAE * CLAIRE DU VAGUE — Moderator. Professional panelist wrangler. Speaks only in pre-approved key messages. * DR. BLAKE THERESE — Systems biologist turned consultant. Confident. Unclear. * LEONTYNE GRIMM — CEO of HelixBioTrust. Appears remotely. Transmits authority in

South Korea’s rise from a war-torn nation in the 1950s to a global technological powerhouse is nothing short of extraordinary. However, as we approach 2025 and beyond, the challenge is to ensure that the big bets which fueled past success have not come at the cost of future

Polygenic risk scores (PRS) are the latest oracle in healthcare’s quest to predict fate. The basic idea sounds beguilingly simple: take the tiny genetic influences scattered across the genome and sum them up into one risk number. If one mutation can’t foretell disease, perhaps hundreds of thousands of

“Excess capacity” – not a phrase one expects to hear in a high-growth industry riding on the coattails of pharmaceutical innovation. Yet in the once-overheated world of contract research and manufacturing, signs of a glut are emerging. Europe’s gleaming labs and China’s biotech parks, which expanded feverishly